
    
      Treatment includes 6 courses of chemoimmunotherapy, the first three courses with an high dose
      methotrexate-based combination (MATRIX) followed by other three courses of R-ICE combination
      and finally a BCNU-thiotepa- containing conditioning and subsequent autologous stem cell
      transplantation.

      MATRIX (courses 1, 2, 3):

      Rituximab 375 mg/m2, Methotrexate 3.5 g/m2, Cytarabine 2 g/m2, Folinic rescue 15 mg/m2,
      Thiotepa 30 mg/m2, Intrathecal liposomial cytarabine 50 mg, rHuG-CSF 2,5 g/kg s.c.

      R-ICE (courses 4, 5, 6):

      Rituximab 375 mg/m2, Etoposide 100 mg/m2/d , Ifosfamide 5 g/m2, Intrathecal liposomial
      cytarabine 50 mg
    
  